Literature DB >> 23974387

Comparison of cancer care and outcomes between a public safety-net hospital and a private cancer center.

Ulas Darda Bayraktar, Sean Warsch, Emerson Chen, Caio Max Lima, Denise Pereira.   

Abstract

We compared the cancer outcomes and care-associated service defects between Jackson Memorial Hospital (ABC), a large public safety-net hospital, and Sylvester Comprehensive Cancer Center (XYZ), a private not-for-profit cancer center in patients with stage II-III colorectal cancer (CC) who received adjuvant chemotherapy (AC) and in patients with diffuse large B cell lymphoma (DLBCL). Colorectal cancer patients treated at ABC were more likely to have undergone urgent surgery. While in the CC cohort, three-year overall survival and relapse-free survival rates were significantly higher among patients treated at XYZ compared with those treated at ABC, there was no significant difference between patients treated for DLBCL in the two hospitals. Colorectal cancer patients treated at ABC were more likely to have undergone urgent surgery, to have delays before surgery or during chemotherapy, and to experience a system/patient-related service defect; whereas were less likely to complete a full course of AC.

Entities:  

Mesh:

Year:  2013        PMID: 23974387     DOI: 10.1353/hpu.2013.0145

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  2 in total

1.  Patient Factors Limit Colon Cancer Survival at Safety-Net Hospitals: A National Analysis.

Authors:  Katherine A Hrebinko; Caroline Rieser; Ibrahim Nassour; Samer Tohme; Lindsay M Sabik; Sidrah Khan; David S Medich; Amer H Zureikat; Richard S Hoehn
Journal:  J Surg Res       Date:  2021-04-08       Impact factor: 2.417

2.  Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute?

Authors:  Sandar Tin Tin; J Mark Elwood; Ross Lawrenson; Ian Campbell; Vernon Harvey; Sanjeewa Seneviratne
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.